How to buy Gain Therapeutics Inc stock (Gain Therapeutics Inc)

Gain Therapeutics Inc is a biotechnology business based in the US. Gain Therapeutics Inc shares (GANX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.59 – an increase of 3.25% over the previous week. Gain Therapeutics Inc employs 29 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Gain Therapeutics stock

Buy Gain Therapeutics Inc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Gain Therapeutics Inc stock price (NASDAQ: GANX)

Use our graph to track the performance of GANX stocks over time.

Gain Therapeutics Inc shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.59
52-week range	$0.89 - $5.33
50-day moving average more info button	$2.08
200-day moving average more info button	$2.17
Wall St. target price	$7.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.07

Is it a good time to buy Gain Therapeutics Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gain Therapeutics Inc price performance over time

Historical closes compared with the close of $1.57 from 2024-12-23

1 week (2024-12-18)	1.95%
1 month (2024-11-26)	-9.25%
3 months (2024-09-25)	-11.80%
6 months (2024-06-25)	20.77%

1 year (2023-12-22)	-36.44%
2 years (2022-12-23)	-50.16%
3 years (2021-12-23)	5.695
5 years (2019-12-22)	N/A

Gain Therapeutics Inc financials

Gross profit TTM	$-7,660,886
Return on assets TTM	-72.96%
Return on equity TTM	-188.83%
Profit margin	0%
Book value	$0.78
Market Capitalization more info button	$40.8 million

TTM: trailing 12 months

Gain Therapeutics Inc share dividends

We're not expecting Gain Therapeutics Inc to pay a dividend over the next 12 months.

You may also wish to consider:

Gain Therapeutics Inc share price volatility

Over the last 12 months, Gain Therapeutics Inc's shares have ranged in value from as little as $0.89 up to $5.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gain Therapeutics Inc's is 0.336. This would suggest that Gain Therapeutics Inc's shares are less volatile than average (for this exchange).

To put Gain Therapeutics Inc's beta into context you can compare it against those of similar companies.

• Fate Therapeutics (FATE.US): 1.879
• Kadmon (KDMN.US): 1.1231
• Chimerix (CMRX.US): 1.128

Gain Therapeutics Inc overview

Gain Therapeutics, Inc. , a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland. .

Frequently asked questions

null
What percentage of Gain Therapeutics Inc is owned by insiders or institutions?
Currently 5.094% of Gain Therapeutics Inc shares are held by insiders and 7.961% by institutions. How many people work for Gain Therapeutics Inc?
Latest data suggests 29 work at Gain Therapeutics Inc. When does the fiscal year end for Gain Therapeutics Inc?
Gain Therapeutics Inc's fiscal year ends in December. Where is Gain Therapeutics Inc based?
Gain Therapeutics Inc's address is: 4800 Montgomery Lane, Bethesda, MD, United States, 20814 What is Gain Therapeutics Inc's ISIN number?
Gain Therapeutics Inc's international securities identification number is: US36269B1052